Dexcom G7 Continuous Glucose Monitoring System secured CE Mark

 

With Dexcom G7, real-time glucose readings are sent automatically to a compatible display device. (Photo: Business Wire)

KUALA LUMPUR, March 15 -- DexCom Inc, the global leader in real-time continuous glucose monitoring for people with diabetes, has announced securing CE Mark (Conformité Européenne) for the Dexcom G7 Continuous Glucose Monitoring (CGM) System for people with diabetes in Europe age two years and older, including pregnant women.

“Today marks an incredible milestone for our company and for people with diabetes in Europe,” said chairman, president and chief executive officer of Dexcom, Kevin Sayer, in a statement.

“This all-new platform offers an incredibly powerful CGM that is simple to use, providing our users with insightful glucose data on one screen that helps them spend less time managing diabetes and more time doing the things they love. Dexcom G7 takes everything people love about G6 and makes it even better.”

Dexcom G7 offers a better way to help users gain greater control of their diabetes, so that they can manage it more confidently each day.

Its low-profile, all-in-one wearable warms up faster than any other CGM on the market, sending real-time glucose readings automatically to a compatible smart device or receiver, no fingersticks required.

Dexcom G7 also offers a suite of customisable alerts that can warn of high or low glucose levels and help users spend more time in range. Industry-leading remote monitoring and reporting capabilities also allow users to stay connected with their loved ones and care teams anytime, anywhere.

New features with Dexcom G7 include 60 per cent smaller, all-in-one, discreet wearable, developed in partnership with Verily; 12-hour grace period to replace finished sensors for a more seamless transition between sessions; and, Direct to Apple Watch (anticipated future software release).

Dexcom is also working closely with its insulin pump partners to integrate Dexcom G7 into current and future automated insulin delivery systems as quickly as possible.

Dexcom expects to initiate a launch of Dexcom G7 in Europe in the next several weeks. The company also plans to introduce an updated CGM algorithm in 2022, driving the next step forward in CGM sensor performance.

More details at www.dexcom.com.

-- BERNAMA